FDA Panel: Reformulated OxyContin Did Not Reduce Overall Abuse

Posted 10/23/20

An FDA advisory committee overwhelmingly panned the idea that Purdue Pharma’s abuse-deterrent formulation (ADF) of oxycodone (OxyContin) “meaningfully reduced” overall opioid abuse, overdose and death.

Want to keep reading?

Subscribers get exclusive access to DHI's extensive library of content, covering top-of-mind issues and trends for today's healthcare executive.

Current Survey

Contact

Digital Health Insights

710 Avis Drive, Suite 200
Ann Arbor, MI 48108

 

Phone: 1.734.665.0000

 

Questions, comments? Submit your feedback below!
  • This field is for validation purposes and should be left unchanged.